Comparison of first-line chemotherapy based on irinotecan or other drugs to treat non-small cell lung cancer in stage IIIB/IV: a systematic review and meta-analysis

The Evolution of Therapies in Non-Small Cell Lung Cancer

(2015) Vishal Boolell et al.   Cancers

Safety and efficacy of first-line bevacizumab combination therapy in Chinese population with advanced non-squamous NSCLC: data of subgroup analyses from MO19390 (SAiL) study

(2013) C. C. Zhou et al.   Clinical & Translational Oncology

Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results

(2010) S. R. Park et al.   ANNALS OF ONCOLOGY

Comparison of Nedaplatin and Irinotecan for Patients with Squamous and Nonsquamous Cell Carcinoma of the Lung: Meta-Analysis of Four Trials

(2010) Fumihiro Oshita et al.   Journal of Thoracic Oncology

Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study

(2010) Lucio Crinò et al.   LANCET ONCOLOGY

Racial Differences in Advanced Colorectal Cancer Outcomes and Pharmacogenetics: A Subgroup Analysis of a Large Randomized Clinical Trial

(2009) Hanna K. Sanoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124

(2009) Primo N. Lara et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I study of combination chemotherapy with irinotecan hydrochloride and nedaplatin for cervical squamous cell carcinoma: Japanese gynecologic oncology group study

(2009) Yamamoto   ONCOLOGY REPORTS

UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma

(2008) Chun-Yu Liu et al.   CANCER

Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first‐line chemotherapy with second‐line crossover in patients with advanced nonsmall cell lung cancer

(2008) Ji‐Youn Han et al.   CANCER